Reuters logo
BRIEF-Genocea's Genital Herpes Immunotherapy GEN-003 demonstrates significant reduction of viral shedding in phase 2b clinical trial
2016年9月29日 / 中午12点02分 / 1 年前

BRIEF-Genocea's Genital Herpes Immunotherapy GEN-003 demonstrates significant reduction of viral shedding in phase 2b clinical trial

Sept 29 (Reuters) - Genocea Biosciences, Inc. :

* Study achieved its primary endpoint

* Genocea’s Genital Herpes Immunotherapy GEN003 demonstrates significant reduction of viral shedding in phase 2b clinical trial

* Phase 3 expected to start in 2h 2017 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below